Brazilian startup creates identification of Coronavirus and is featured in Forbes Magazine
Analyzes indicate predisposition of individuals and suggest preventive care
These questions that drive research, scientists, medical professionals, are shared in discussions, analyzes in any environment of the daily routine of the human being - whether at home, in remote work, on social networks and, of course, in the press news of everyone the countries. And they also occur in Brazil, there would be no difference.
The website of Forbes magazine, the world's largest publication in the economic area, published in March (see print of the publication attached), a special report on the challenges of the Coronavirus pandemic in various segments of society.
Accelerated by the Federation of Industries of the State of Paraná (Fiep), the startup FullDNA created a method capable of identifying the genetic susceptibility index of each person to Covid-19. "Since last year, we have been developing an algorithm to analyze the risk of contamination of some types of viruses. Diseases such as SARS (severe acute respiratory syndrome) and Influenza have been analyzed. As soon as the numbers of those infected with coronavirus started to multiply, due to the imminent risk, we appointed a team to develop a specific algorithm: a system that reads genetic data and indicates the person's susceptibility to coronavirus"
The study indicates which people are more prone to the disease, so that more detailed protective measures are taken. The tests have already started and can be performed on people of any age. The collection is quick and painless, through the analysis of the mucosa of the mouth, but, for now, only health professionals can request the acquisition of the kit for the exam.
FullDNA came about through the initiative of a team of scientists, geneticists, doctors and bioinformatics from Brazil and several countries, who had several goals in common. The most challenging:
"It is known of the many risks that human beings have to develop a multitude of diseases, serious or not. If you detect this possibility in advance, you can act preventively to neutralize the future risk. People will live longer, better, safely, without being subject to surprises", says Dr. José Irineu Golbspan, medical doctor and director for Latin America at FullDNA.
In this way, FullDNA is already in five countries, used by more than 1 million people. In Brazil, the goal is to expand to 27 Brazilian states, including collection centers, with the goal of reaching more than 50,000 tests carried out in the country by the end of 2020.